Phase II study of stereotactic radiotherapy combined with an anlotinib in the treatment of spinal malignant tumors

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017928

Enrollment

Unknown

Registered

2018-08-22

Start date

2018-08-22

Completion date

Unknown

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spine tumor

Interventions

Case series:stereotactic radiotherapy combined with an anlotinib

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with primary tumors of Spine tumors

Exclusion criteria

Exclusion criteria: 1. Local lesions are not suitable for SRS; 2. Body poor constitution could not accept SRS

Design outcomes

Primary

Measure	Time frame
local control;	—

Countries

China

Contacts

Public ContactZhuang Hongqing

Peking University Third Hospital

hongqingzhuang@163.com+86 13051776232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026